Thyrocare Technologies Ltd (THYROCARE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539871 | NSE: THYROCARE | Hospital & Healthcare Services | Small Cap

Thyrocare Tech. Share Price

423.40 -4.70 -1.10%
as on 05-Dec'25 12:12

Thyrocare Technologies Ltd (THYROCARE) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 539871 | NSE: THYROCARE | Hospital & Healthcare Services | Small Cap

DeciZen - make an informed investing decision on Thyrocare Tech.

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Thyrocare Technologies stock performance -

Key Ratios
mw4me loader
P/E Ratio (CD):
53.34
Market Cap:
6,813.7 Cr.
52-wk low:
219.3
52-wk high:
538

Is Thyrocare Technologies Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Thyrocare Tech.: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Thyrocare Technologies Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 25.7%21%33.9%31.5%35.3%38.5%48.4%17.6%18.8%27.3%-
Value Creation
Index
0.80.51.41.31.51.82.50.30.31.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 241304356403434495589527572687763
Sales YoY Gr.-26.3%17.1%13.1%7.8%13.9%19.1%-10.6%8.6%20.2%-
Adj EPS 3.23.85.65.25.76.79.94.14.55.48
YoY Gr.-21.1%46.9%-8.7%9.9%18.4%47.9%-58.2%8.9%18.9%-
BVPS (₹) 22.52527.327.222.926.83333.432.934.140.2
Adj Net
Profit
51.16290.981.689.810615765.771.785.2128
Cash Flow from Ops. 67.889.6107100168115113129168191-
Debt/CF from Ops. 00.10000000.10-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 12.4%9.6%5.3%20.2%
Adj EPS 6%-1.1%-18.5%18.9%
BVPS4.7%8.3%1.2%3.7%
Share Price - 3.9% 25.6% 25.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
15.91621.418.622.426.83312.413.515.921.6
Op. Profit
Mgn %
39.138.340.938.34034.74023.424.427.830
Net Profit
Mgn %
21.220.425.520.220.621.826.712.212.312.416.8
Debt to
Equity
00000000000
Working Cap
Days
6051444247591542401317374
Cash Conv.
Cycle
19191513373158351047

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Thyrocare Technologies Ltd.

Standalone Consolidated
TTM EPS (₹) 7.6 8
TTM Sales (₹ Cr.) 708 763
BVPS (₹.) 39.1 40.2
Reserves (₹ Cr.) 463 481
P/BV 10.94 10.64
PE 56.72 53.34
From the Market
52 Week Low / High (₹) 219.33 / 537.97
All Time Low / High (₹) 135.55 / 537.97
Market Cap (₹ Cr.) 6,814
Equity (₹ Cr.) 159.2
Face Value (₹) 10
Industry PE 90.5

Management X-Ray of Thyrocare Tech.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *100.00100.00100.00100.00100.00100.00100.00100.00100.0085.84
* Pledged shares as % of Promoter's holding (%)

Valuation of Thyrocare Tech. - Consolidated Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Thyrocare Tech.

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales241304356403434495589527572687
Operating Expenses 147189212249261323353404433496
Manufacturing Costs11131216191723307291
Material Costs708195111117164170163167191
Employee Cost 26323543495861106108127
Other Costs 406269797684991058788
Operating Profit 94115145154174171236123139191
Operating Profit Margin (%) 39.0%37.9%40.6%38.3%40.0%34.6%40.0%23.3%24.3%27.8%
Other Income 7122310712298915
Interest 1001213564
Depreciation 18182026323034394755
Exceptional Items 0-27-20-700000
Profit Before Tax 82821451381401522288996145
Tax 30395253523952242655
Profit After Tax 5243938588113176646991
PAT Margin (%) 21.5%14.1%26.2%21.1%20.4%22.9%29.9%12.2%12.2%13.2%
Adjusted EPS (₹)3.22.75.85.45.67.111.14.24.55.7
Dividend Payout Ratio (%)104%125%57%124%30%118%45%144%134%123%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 363403440431363424523530522542
Share Capital 54545453535353535353
Reserves 309349387378310371470477469489
Minority Interest0000000110
Debt07033000130
Long Term Debt07033000110
Short Term Debt0000000020
Trade Payables2178222517244076
Others Liabilities 4223272882913082065365
Total Liabilities 407434474470469540848761629684

Fixed Assets

Gross Block318277336355359366423461501543
Accumulated Depreciation5918376190113138167195245
Net Fixed Assets 259259299294269253285294306297
CWIP 117015832314
Investments 931041209590126146144162162
Inventories11141718212325284847
Trade Receivables861012164593854373
Cash Equivalents 10121210111614284054
Others Assets 2521163957692821802737
Total Assets 407434474470469540848761629684

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 6890107100168115113129168191
PBT 82821451371461532288796147
Adjustment 1743924322321657173
Changes in Working Capital 162-134-18-7963013
Tax Paid -32-40-49-61-45-43-57-28-29-41
Cash Flow From Investing Activity -18-42-43-121-49-24-39-91-53
Capex -14-36-44-39-10-21-15-42-61-45
Net Investments -7-10-42610-32-91-312
Others 354215111-9
Cash Flow From Financing Activity -45-49-64-94-165-62-89-86-85-130
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0003000022-22
Interest Paid 000-0-0-0-2-2-7-3
Dividend Paid -38-40-54-27-132-53-79-79-95-95
Others -7-8-10-69-33-9-8-5-5-10
Net Cash Flow 5-0-0-54404-88

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)16.2211.1922.1219.5322.2628.7537.1812.2313.2117.04
ROCE (%)25.6621.0433.8931.4835.2738.5148.4217.6118.7527.25
Asset Turnover Ratio0.660.720.780.850.930.980.850.650.821.05
PAT to CFO Conversion(x)1.312.091.151.181.911.020.642.022.432.1
Working Capital Days
Receivable Days98810122343624131
Inventory Days14151616161615182425
Payable Days7715234652454570111

Thyrocare Technologies Ltd Stock News

Thyrocare Technologies Ltd FAQs

The current trading price of Thyrocare Tech. on 05-Dec-2025 12:12 is ₹423.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Thyrocare Tech. stood at ₹6,813.7.
The latest P/E ratio of Thyrocare Tech. as of 04-Dec-2025 is 56.72.
The latest P/B ratio of Thyrocare Tech. as of 04-Dec-2025 is 10.94.
The 52-week high of Thyrocare Tech. is ₹538.0 and the 52-week low is ₹219.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Thyrocare Tech. is ₹707.5 ( Cr.) .

About Thyrocare Technologies Ltd

Thyrocare Technologies Ltd. is India's first and most advanced Totally Automated Laboratory having its strong presence in several cities / towns in India and internationally. Thyrocare is India's first fully automated diagnostic laboratory with a focus on providing quality at affordable costs to laboratories and hospitals in India and other countries. Thyrocare operates with a Centralized Processing Laboratory (CPL) in Mumbai - India for esoteric tests; and Regional Processing Laboratory in major metro cities of India and other parts of Asia. It has focus on strong technologies, strong brands and strong systems that enable all laboratories to give their clients the best of science and technology at an affordable cost. Thyrocare became one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations like ISO 9001-2000 rating as early as 2001, which is now escalated to ISO 9001:2008 and CAP (College of American Pathologists) certification in 2007.

Business area of the company

Thyrocare Technologies is an India-based healthcare service provider. The Company operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The Company offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The Company offers cancer diagnosis and water testing through its brands Nueclear and Whaters, respectively.

Major events and milestones

  • 2000: The company was incorporated in the name and style of ‘Thyrocare Technologies Limited’ and received a certificate for commencement of operations.
  • 2001: The company received ISO 9001 certification.
  • 2001: The company commenced commercial operations under the brand name ‘Thyrocare’ pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996).
  • 2005: The company received NABL accreditation.
  • 2006: The company issued certain fully convertible debentures aggregating to Rs 250 million to BCCL.
  • 2007: The company receives accreditation from the College of American Pathologists (CAP).
  • 2010: The company issued certain compulsorily convertible debentures aggregating to Rs 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to Rs 1,250 million from its Promoters and certain other persons.
  • 2010: The company launched wellness packages under the brand name ‘Aarogyam’.
  • 2011: The company migrated to ‘total laboratory automation system’ installed by Siemens for efficient handling of increasing volumes.
  • 2012: NVP acquired certain Equity Shares aggregating to Rs 1,200 million from certain entities.
  • 2013: EIF acquired certain Equity Shares from Agalia.
  • 2013: The company’s subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation.
  • 2014: The company had installed, India’s first and the world’s longest track automation system for seamless sample movements from Siemens Limited.
  • 2014: The company commissioned the operations in medical cyclotron facility in Navi Mumbai.
  • 2014: The company’s subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations.
  • 2015: The company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily.
  • 2015: The company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name ‘WHATERS’. These tests, at present, include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing.
  • 2015: The company’s subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception.
  • 2015: The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily.
  • 2015: The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name ''WHATERS''. These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing.
  • 2015: The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception.
  • 2016: Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities.
  • 2016: Entered the Public listed sphere of healthcare – IPO.
  • 2016: Launched 2 new RPLs and NGSP Certification:- Certified with National Glycohemoglobin Standardization Program Certification (NGSP) for HbA1c Testing, and Launched 2 Regional Processing Laboratories- Bhopal and Bangalore, with state-of-the-art automations efficient as CPL, controlled via a centralized server.
  • 2016: Aarogyam Today:  Launched a second monthly publication addressing daily health concerns - Aarogyam Today.
  • 2016: Launched IFA (Immunofluorescence) for Autoimmunity testing.
  • 2017:  Launched Molecular Biology Division (PCR).
  • 2018: Patna Regional Processing Laboratory (RRL) was launched.
  • 2018: Last Mile Executive (LMEs) pickup service started in 15 plus cities.
  • 2018: Thyrocare and Thyroshop Mobile App were launched.
  • 2020: Thyrocare Technologies launching Blood-based Cancer Screening Profile.
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×